Synergy Pharma, Regarding Mention Of Diarrhea Side Effects In FDA Approval Of Plecanatide, Highlights To Benzinga Low Level Of Clinical Trial Discontinuation Rates: 4% Due to Diarrhea vs 2% for Placebo